We cordially invite you to the Innovation Forum Cellular Allergy at BASEL LIFE 2019 on the 12th of September 2019 at the congress center in Basel.
Please join our distinguished speakers from academia and industry to hear about new perspectives on cellular and molecular allergy research and current treatment and monitoring possibilities.
In fact, the treatment of food allergies rather than alleviating symptoms may soon become reality. Dr. Wayne Shreffler (Massachusetts General Hospital, Boston, USA) will present the latest breakthroughs in applying immunotherapy in allergy, while Dr. Alexandra Santos (King`s College London, United Kingdom) will explain how basophil activation testing (BAT) can improve allergy diagnosis and subsequent monitoring of the treatment.
Dr. Alexander Eggel (University Hospital Bern, Switzerland) will share his insights concerning novel therapeutic strategies to fight allergies based on current molecular biology knowledge and Dr. Christoph Heusser (Novartis Basel, Switzerland) will talk about mechanistic differences between the anti-IgE antibodies omalizumab and ligelizumab that allow therapy in allergic asthma and chronic urticaria.
Prof. Dr. Jean-Phillipe Girard (IPBS Toulouse, France) recently discovered how distinct allergens highjack a human cytokine to elicit an immune response in allergic asthma, while Prof. Dr. Matthias Wymann (University of Basel, Switzerland) will dissect novel findings of protein kinase signalling pathways that trigger allergic reactions. The lipid kinase PI3Kdelta plays an important role in immune receptor signaling and Dr. Augustin Amour (GSK, Stevenage, United Kingdom) will focus specifically on the role of PI3K signalling in allergy and asthma.
Basophil cells are key mediators of allergic immune responses and share several components with other immune cells, especially B-cells. Therefore, the inhibition of basophil activation is gaining more and more interest also in the leukemia field as a surrogate biomarker of the B-cell receptor signaling. The BAT inhibition assay is a concrete pharmacodynamic marker for several new drugs like Ibrutinib and Idelalisib. Prof Dr. Bruce Bochner (Northwestern Medicine, Chicago, USA) will show how these helpful drugs in leukemia treatment could also play a primary role in allergy treatment.
Have a look on the Innovation Forum 2019 Cellular Allergy program: